Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:NEOS
- CUSIP: N/A
- Web: www.neostx.com
- Market Cap: $238.04 million
- Outstanding Shares: 28,081,000
- 50 Day Moving Avg: $8.88
- 200 Day Moving Avg: $8.88
- 52 Week Range: $4.85 - $9.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.41
- P/E Growth: -0.03
- Annual Revenue: $15.62 million
- Price / Sales: 15.10
- Book Value: $0.93 per share
- Price / Book: 9.03
- EBIDTA: ($69,700,000.00)
- Net Margins: -511.74%
- Return on Equity: -611.78%
- Return on Assets: -80.97%
- Debt-to-Equity Ratio: 2.33%
- Current Ratio: 3.04%
- Quick Ratio: 2.84%
- Average Volume: 1.24 million shs.
- Beta: -0.9
- Short Ratio: 6.71
Frequently Asked Questions for Neos Therapeutics (NASDAQ:NEOS)
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics, Inc. (NASDAQ:NEOS) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.83) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.83). The firm had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. View Neos Therapeutics' Earnings History.
When will Neos Therapeutics make its next earnings announcement?
Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?
4 brokers have issued twelve-month price objectives for Neos Therapeutics' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' stock price to reach $16.75 in the next twelve months. View Analyst Ratings for Neos Therapeutics.
What are analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (9/12/2017)
- 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) FDA approval of Cotempla XR-ODT in June of this year, with commercial availability in Fall of 2017, 2) On June 27, 2017, Neos announced the pricing of an underwritten public offering of $32.4MM value of common stock at a price of $6.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos." (8/9/2017)
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Teligent (TLGT), Corium International (CORI), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Collegium Pharmaceutical (COLL), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Concordia International Corp. (CXRX), SCYNEXIS (SCYX), Amryt Pharma PLC (AMYT) and Evoke Pharma (EVOK).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Alan Heller, Chairman of the Board
- Vipin K. Garg Ph.D., President, Chief Executive Officer, Director
- Richard Eisenstadt, Chief Financial Officer
- Dorothy Engelking, Vice President of Regulatory Affairs
- Thomas P McDonnell, Chief Commercial Officer
- Beth P. Hecht, Director
- Paul R. Edick, Non-Executive Director
- Bryant E. Fong, Non-Executive Director
- Gregory J. Robitaille, Non-Executive Director
- John P. Schmid, Non-Executive Director
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
Who owns Neos Therapeutics stock?
Neos Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include
FLYNN JAMES E
(9.08%), Franklin Resources Inc. (9.65%), Vanguard Group Inc. (3.28%), Stonepine Capital Management LLC (2.07%), State Street Corp (1.16%) and Columbus Circle Investors (1.21%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell. View Institutional Ownership Trends for Neos Therapeutics.
Who sold Neos Therapeutics stock? Who is selling Neos Therapeutics stock?
Who bought Neos Therapeutics stock? Who is buying Neos Therapeutics stock?
Neos Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Essex Investment Management Co. LLC, Russell Investments Group Ltd., Columbus Circle Investors, Vanguard Group Inc., DAFNA Capital Management LLC, State Street Corp and Virtu KCG Holdings LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell. View Insider Buying and Selling for Neos Therapeutics.
How do I buy Neos Therapeutics stock?
Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Neos Therapeutics stock can currently be purchased for approximately $8.40.
Earnings History for Neos Therapeutics (NASDAQ:NEOS)Earnings History by Quarter for Neos Therapeutics (NASDAQ NEOS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.83)||($0.83)||$4.91 million||View||Listen|
|5/9/2017||Q1 2017||($0.94)||($0.87)||$5.63 million||View||Listen|
|3/14/2017||Q4 2016||($1.36)||($1.14)||$3.50 million||View||N/A|
|11/10/2016||Q3 2016||($1.64)||($1.61)||$1.58 million||View||N/A|
|8/11/2016||Q2||($1.16)||($1.65)||$1.48 million||$1.49 million||View||Listen|
|5/16/2016||Q1||($0.87)||($0.79)||$1.50 million||$2.58 million||View||Listen|
|9/3/2015||Q215||($4.31)||($7.76)||$1.70 million||$1.48 million||View||Listen|
Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
Current Year EPS Consensus Estimate: $-3.06 EPS
Next Year EPS Consensus Estimate: $-1.31 EPS
Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Neos Therapeutics (NASDAQ:NEOS)
Insider Ownership Percentage: 5.17%Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Institutional Ownership Percentage: 44.29%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/31/2016||Bryant Fong||Director||Buy||1,500||$6.54||$9,810.00|| |
|8/25/2016||Richard I Eisenstadt||CFO||Buy||3,710||$6.82||$25,302.20|| |
|6/13/2016||Juergen Martens||Insider||Buy||10,000||$9.90||$99,000.00|| |
|5/19/2016||Alan L Heller||Director||Buy||10,000||$7.61||$76,100.00|| |
|5/19/2016||Thomas P Mcdonnell||Insider||Buy||3,000||$7.56||$22,680.00|| |
|5/18/2016||Gregory J Robitaille||Director||Buy||7,442||$7.55||$56,187.10|| |
|4/20/2016||Presidio Partners 2007, L.P.||Major Shareholder||Sell||20,367||$9.98||$203,262.66|| |
|4/15/2016||Presidio Partners 2007, L.P.||Major Shareholder||Sell||57,968||$10.23||$593,012.64|| |
Headline Trends for Neos Therapeutics (NASDAQ:NEOS)
Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
|Corporate News Blog - Neos Therapeutics Receives FDA’s Approval for Adzenys ER(TM) Extended-Release Oral Suspension, its Third Treatment for ADHD|
finance.yahoo.com - September 20 at 6:53 AM
|Neos Therapeutics (NEOS) versus The Competition Head to Head Analysis|
www.americanbankingnews.com - September 19 at 2:30 PM
|Neos Therapeutics, Inc. (NEOS) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - September 19 at 2:38 AM
|Financial Comparison: Neos Therapeutics (NEOS) vs. Its Competitors|
www.americanbankingnews.com - September 17 at 4:26 AM
|Neos Therapeutics (NEOS) Granted U.S. FDA Approval of Adzenys ER (amphetamine|
www.streetinsider.com - September 17 at 2:06 AM
|Neos Therapeutics to launch third medication in ADHD franchise in January 2018|
www.nasdaq.com - September 16 at 6:54 AM
|BRIEF-Neos Therapeutics receives U.S. FDA approval|
www.reuters.com - September 16 at 6:54 AM
|Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older|
finance.yahoo.com - September 16 at 6:53 AM
|Neos Therapeutics shares fall after FDA approves new formulation of ADHD drug|
finance.yahoo.com - September 16 at 6:53 AM
|Zacks: Brokerages Expect Neos Therapeutics, Inc. (NEOS) Will Post Earnings of -$0.70 Per Share|
www.americanbankingnews.com - September 15 at 4:32 AM
|Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally ... - Nasdaq|
www.nasdaq.com - September 7 at 6:39 AM
|BRIEF-Neos Therapeutics announces launch of Cotempla XR-OD extended-release orally disintegrating tablets for treatment of ADHD|
www.reuters.com - September 6 at 6:45 AM
|Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old|
finance.yahoo.com - September 6 at 6:45 AM
|Neos Therapeutics to Participate in Three September Conferences - GlobeNewswire (press release)|
globenewswire.com - August 31 at 7:42 AM
|Neos Therapeutics to Participate in Three September Conferences|
finance.yahoo.com - August 31 at 7:42 AM
|Orally Disintegrating Tablets Market to Reach US$ 27 Bn by 2025 - Persistence Market Research|
www.prnewswire.com - August 29 at 5:16 AM
|Neos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.70 Per Share|
www.americanbankingnews.com - August 27 at 2:24 PM
|Neos Therapeutics, Inc. (NEOS) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - August 25 at 2:38 AM
|Neos Therapeutics, Inc. (NEOS) Rating Increased to Strong-Buy at Zacks Investment Research|
www.americanbankingnews.com - August 23 at 6:14 AM
|ValuEngine Upgrades Neos Therapeutics, Inc. (NASDAQ:NEOS) to Sell|
www.americanbankingnews.com - August 12 at 7:34 PM
|Cantor Fitzgerald Analysts Give Neos Therapeutics, Inc. (NEOS) a $20.00 Price Target|
www.americanbankingnews.com - August 9 at 11:38 PM
|Neos Therapeutics, Inc. (NEOS) Issues Earnings Results|
www.americanbankingnews.com - August 9 at 5:54 PM
|BRIEF-Neos Therapeutics Q2 loss per share $0.83|
www.reuters.com - August 9 at 3:01 AM
|Investor Network: Neos Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - August 9 at 3:01 AM
|Neos Therapeutics Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 9 at 3:01 AM
|Neos Therapeutics reports 2Q loss|
finance.yahoo.com - August 9 at 3:01 AM
|Cantor Fitzgerald Weighs in on Neos Therapeutics, Inc.'s FY2017 Earnings (NEOS)|
www.americanbankingnews.com - August 3 at 9:50 AM
|Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017|
feeds.benzinga.com - August 2 at 8:21 AM
|Neos Therapeutics, Inc. (NEOS) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - July 31 at 6:46 PM
|Cantor Fitzgerald Initiates Coverage on Neos Therapeutics, Inc. (NASDAQ:NEOS)|
www.americanbankingnews.com - July 31 at 5:31 PM
|Neos Therapeutics, Inc. (NASDAQ:NEOS) Expected to Post Earnings of -$0.83 Per Share|
www.americanbankingnews.com - July 20 at 12:24 AM
|Neos Looks Attractive With Short And Long Term Catalysts|
seekingalpha.com - July 1 at 3:36 AM
|Attention To Details: Neos' ADHD Portfolio|
www.benzinga.com - June 27 at 6:53 PM
|BRIEF-Neos Therapeutics announces proposed offering of common stock|
www.reuters.com - June 27 at 6:53 PM
|Form 8-K Neos Therapeutics, Inc. For: Jun 26|
www.streetinsider.com - June 27 at 6:53 PM
|Neos Therapeutics Announces Pricing of Underwritten Public Offering of $32.4 Million of Common Stock|
finance.yahoo.com - June 27 at 6:53 PM
|Neos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.83 Per Share|
www.americanbankingnews.com - June 23 at 10:24 PM
|Neos nets second ADHD drug approval - for no-swallow, dissolve pill|
www.bizjournals.com - June 23 at 7:19 PM
|Shire wins U.S. approval for long-acting ADHD drug|
finance.yahoo.com - June 21 at 5:56 AM
|Neos Therapeutics, Inc. (NEOS) Lifted to "Sell" at ValuEngine|
www.americanbankingnews.com - June 20 at 11:40 PM
|Neos Therapeutics Slides Despite FDA Approval|
247wallst.com - June 20 at 7:53 PM
|Shire's long-acting ADHD drug wins U.S. approval|
finance.yahoo.com - June 20 at 7:53 PM
|Neos Therapeutics, Inc. (NEOS) Receives Outperform Rating from BMO Capital Markets|
www.americanbankingnews.com - June 20 at 12:28 PM
|Neos Therapeutics Says ADHD Drug Cotempla XR-ODT Gets FDA Approval|
www.nasdaq.com - June 20 at 7:45 AM
|Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old|
finance.yahoo.com - June 19 at 10:53 PM
|Neos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference|
finance.yahoo.com - June 14 at 9:25 AM
|Neos Therapeutics, Inc. (NEOS) Upgraded to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - June 13 at 4:40 PM
|Neos Therapeutics Inc (NEOS) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - June 10 at 7:26 AM
|BRIEF-Neos Therapeutics enters into first amendment to its existing facility agreement with lenders|
www.reuters.com - June 5 at 7:27 PM
|Zacks Investment Research Upgrades Neos Therapeutics Inc (NEOS) to Buy|
www.americanbankingnews.com - June 3 at 7:12 AM
Neos Therapeutics (NEOS) Chart for Wednesday, September, 20, 2017